WADA Statement on the Salbutamol Threshold/Decision Limit / World Anti-Doping Agency (WADA). - Montreal : WADA, 2018
Contents:
1. HISTORICAL BACKGROUND
1.1 The List Pre-World Anti-Doping Code
1.2 Evolution of the rules for β2-agonists and more specifically salbutamol under the WADC Prohibited List
1.3 Consolidation of the salbutamol threshold over the years
1.4 Measurement of salbutamol urinary concentration
2. CONCEPT OF THE CONTROLLED EXCRETION STUDY
3. INTEGRATION OF THE MEASUREMENT UNCERTAINTY
3.1 Compliance decisions for Threshold Substances: Thresholds, Measurement Uncertainties and Decision Limits
3.2 Rule applied until 1 September 2010
3.3 Rule applied from 1 September 2010
4. SPECIFIC GRAVITY
5. CONCLUSIONS
6. CONSULTATION AND PEER REVIEW
7. REFERENCES
8. COMPOSITION OF WADA SCIENTIFIC COMMITTEES
8.1 COMPOSITION OF WADA HEALTH, MEDICAL AND RESEARCH COMMITTEES (2001-2018)
8.2 COMPOSITION OF LIST EXPERT GROUPS (2003-2018)
8.3 COMPOSITIONS OF LABORATORY EXPERT GROUPS (2002-2018)
